|Carolyn D. Britten, MD|
CANCER DRUG DEVELOPMENT EXPERT CAROLYN D. BRITTEN, MD, JOINS MUSC HOLLINGS CANCER CENTER AND WILL LEAD PHASE I CLINICAL TRIALS PROGRAM
July 23, 2012, Charleston, SC – Carolyn D. Britten, MD, a noted expert in cancer drug development, has joined the Hollings Cancer Center at the Medical University of South Carolina and will serve as director of the cancer center’s growing Phase I Clinical Trials Research Program.
Britten, an associate professor of Medicine, is a medical oncologist. She was recruited from UCLA’s Jonsson Comprehensive Cancer Center where her leadership positions from 2001-2012 included serving as director of Protocol-Specific Research Support and associate director of the Signal Transduction and Therapeutics Program.
"We are glad to have Dr. Britten join the MUSC Hollings team. Known for her knowledge and experience in Drug Discovery and Phase I clinical trials, she will work closely with our clinicians, researchers and industry partners to build a renowned Phase I program," said Hollings Director Dr. Andrew S. Kraft. "Her contributions will lead to more novel early-phase treatment options for our cancer patients and help transition promising laboratory research into the clinic."
In Phase I trials, researchers test an experimental drug or treatment for the first time in a small group of patients (20-80) to evaluate its safety, determine a safe dosage range, and identify side effects. Hollings has 30 Phase I trials in progress and 11 scheduled to open this year.
By earning designation from the National Cancer Institute, recruiting accomplished scientists and investing in technology and infrastructure, Dr. Britten said MUSC and Hollings demonstrate a commitment to developing an impressive Phase I program.
“Phase I trials are where we begin to explore whether a new drug that looks promising in the lab can make a difference in the lives of patients,” Britten said. “There is a keen interest in drug development at MUSC, and I look forward to collaborating with the basic-, translational-, and clinical researchers here.”